🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This event is special 💙 For every birdie made on No. 15, Cologuard Classic by Exact Sciences is donating $1,500 to send cancer survivors to next year’s event. Survivors walked down the fairway with the final group and tournament host @JerryKelly13PGA!

These flags represent young lives that can be saved if you take action. 🚨 Thank you to our partners in the fight alongside us. 💙 American Cancer Society Cancer Action Network, American Cancer Society, ACS National Colorectal Cancer Roundtable, ACG, American Gastroenterological Association (AGA), ASGE GI Endoscopy, AMSURG Corp, ABGH, TheBlueHatFoundation, C4

We’re still reminiscing on the 2025 Cologuard Classic by Exact Sciences! Take a look back at the tournament’s impact beyond the golf course: spr.ly/60160mnXY Cologuard Classic by Exact Sciences

How can you maintain a healthy colon and take steps to get ahead of colorectal cancer? Get started with these five tips from Jordan Karlitz, MD, FACG, AGAF: spr.ly/60160QJNK via Katie Couric Media Katie Couric #ColorectalCancerAwarenessMonth

Our most important match yet.

Today we’re announcing the launch of the Cologuard Plus™ test. See why it will transform colorectal cancer screening: spr.ly/6019FRtGF

Don’t mind us; just taking a minute to brag about our incredible #ExactSciencesAthletes! They’ve been killing it on the court, ice, track, in the pool, and beyond. We’re so proud of this group! Learn more about the program: spr.ly/6017FdDdl

This Cancer Prevention and Early Detection Month serves as a reminder about the importance of cancer screening. Together, we’re committed to raising awareness and improving access to tools that catch cancer earlier. Learn more: spr.ly/6010FWg3Q Prevent Cancer Foundation

A comprehensive review published in JAMA Oncology confirms that the Oncotype DX® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity. Learn more: spr.ly/6019FhOx7

With the launch of the Oncodetect™ test, we're advancing the field of molecular residual disease (MRD) testing, providing patients and their healthcare providers with the insights needed to help make informed decisions throughout the treatment process. 🔗 spr.ly/60142VsNw

Do you know which routine cancer screenings you need this year? Are you sure? Double check and make a note to schedule any appointments you’re missing: preventcancer.org/prevention-scr…

Congratulations Jerry Kelly!!🏌🏆

We will be in San Diego this weekend for #DDW2025. We’re sharing strong research and data that predict the Cologuard® test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics. spr.ly/60152SdL7 Digestive Disease Week

Exact Sciences and the Boys and Girls Club of Dane County teamed up on Wednesday to host a basketball camp for club members. wmtv15news.com/2025/05/01/i-w…

Today, we announced our first-quarter 2025 earnings results. For more information, see our press release here: spr.ly/60182x502

📍 Munich, Germany We’re looking forward to sharing how we’re advancing cancer care while connecting with the oncology community this week at #ESMOBreast25. Learn more: spr.ly/6017Nboqb

🎉 Exciting news out of our Cologuard laboratory: we've officially processed 20 million tests! That’s 20M results delivered. Every test tells a story, and as of today, we’ve been part of 20M of them. Here's to earlier detection, one test at a time — and to the next 20M!

From developing new therapies to assessing how well a medical test works, clinical trials have a clear impact on patient care. Thank you to all participants and research professionals who make clinical trials possible. #ClinicalTrialsDay

We’re sharing data across our expanding portfolio at #ASCO25, demonstrating our commitment to advancing cancer care through scientific excellence. Find out more: spr.ly/6011Najrd ASCO

Results to be presented at #ASCO25 confirm the Oncodetect™ test’s role in supporting treatment and surveillance decisions. Building on this momentum and our commitment to innovation, we look forward to introducing the next generation of the test in 2026. spr.ly/6012N2nsk